Modus Therapeutics

Inotrem

This biopharmaceutical company develops immunotherapies targeting the TREM-1 pathway for patients suffering from acute inflammatory syndromes such as septic shock.

Matisse Pharmaceuticals

This biopharmaceutical company develops isupartob sodium, a heparin derivative designed to treat sepsis by neutralising cytotoxic histones in critically ill patients.

Matisse Pharmaceuticals B.V.

This biopharmaceutical company develops heparin-derived medicinal therapies to treat sepsis and septic shock for patients in intensive care units.

PATH EX, Inc.

This company develops a medical device that removes bacteria and endotoxins from the bloodstream to treat sepsis patients in clinical settings.

Adrenomed

This biopharmaceutical company develops monoclonal antibody therapies to restore vascular integrity for critically ill patients suffering from sepsis and septic shock.

Hemotune

This company develops a magnetic blood purification platform using nanoengineered beads to remove specific disease-causing substances for patients with sepsis or requiring gene therapy.

SepsiScan

This company develops bedside imaging devices for real-time microcirculation monitoring and early sepsis diagnosis for intensive care units and hospitals.

AM Pharma

This biopharmaceutical company develops recombinant human alkaline phosphatase therapeutics to treat patients suffering from sepsis-associated acute kidney injury and other severe inflammatory conditions.